Allele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian population

被引:172
作者
Scordo, MG [1 ]
Caputi, AP [1 ]
D'Arrigo, C [1 ]
Fava, G [1 ]
Spina, E [1 ]
机构
[1] Univ Messina, Policlin Univ, Pharmacol Sect, Dept Expt & Clin Med & Pharmacol, I-98125 Messina, Italy
关键词
D O I
10.1016/j.phrs.2004.01.004
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The polymorphic cytochrome P450 isoenzymes (CYPs) 2C9, 2C19 and 2D6 metabolise many important drugs, as well as other xenobiotics. Their polymorphism gives rise to important interindividual and interethnic variability in the metabolism and disposition of several therapeutic agents and may cause differences in the clinical response to these drugs. In this study, we determined the genotype profile of a random Italian population in order to compare the CYP2C9, CYP2C19 and CYP2D6 allele frequencies among Italians with previous findings in other Caucasian populations. Frequencies for the major CYP2C9, CYP2C19 and CYP2D6 mutated alleles and genotypes have been evaluated in 360 unrelated healthy Italian volunteers (210 males and 150 females, aged 19-52 years). Genotyping has been carried out on peripheral leukocytes DNA by molecular biology techniques (PCR, RFLP, long-PCR). CYP2C9, CYP2C19 and CYP2D6 allele and genotype frequencies resulted in equilibrium with the Hardy-Weinberg equation. One hundred and fourteen subjects (31.7%) carried one and 23 subjects (6.4%) carried two CYP2C9 mutated alleles. Sixty-eight (18.9%) volunteers were found to be heterozygous and six (1.7%) homozygous for the CYP2C19*2, while no CYP2C19*3 was detected in the evaluated population. Volunteers could be divided into four CYP2D6 genotypes groups: 192 subjects (53.3%) with no mutated alleles (homozygous extensive metabolisers, EM), 126 (35.0%) with one mutated allele (heterozygous EM), 12 (3.4%) with two mutated alleles (poor metabolisers, PM) and 30 (8.3%) with extracopies of a functional gene (ultrarapid metabolisers, UM). Frequencies of both CYP2C9 and CYP2C19 allelic variants, as well as CYP2D6 detrimental alleles, in Italian subjects were similar to those of other Caucasian populations. Conversely, the prevalence of CYP2D6 gene duplication among Italians resulted very high, confirming the higher frequency of CYP2D6 UM in the Mediterranean area compared to Northern Europe. (C) 2004 Elsevier Ltd. All rights reserved.
引用
收藏
页码:195 / 200
页数:6
相关论文
共 47 条
[1]   PREVALENCE OF CYP2D6 GENE DUPLICATION AND ITS REPERCUSSION ON THE OXIDATIVE PHENOTYPE IN A WHITE-POPULATION [J].
AGUNDEZ, JAG ;
LEDESMA, MC ;
LADERO, JM ;
BENITEZ, J .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1995, 57 (03) :265-269
[2]  
Aklillu E, 1996, J PHARMACOL EXP THER, V278, P441
[3]   HYDROXYLATION POLYMORPHISMS OF DEBRISOQUINE AND MEPHENYTOIN IN EUROPEAN POPULATIONS [J].
ALVAN, G ;
BECHTEL, P ;
ISELIUS, L ;
GUNDERTREMY, U .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1990, 39 (06) :533-537
[4]   Low frequency of defective alleles of cytochrome P450 enzymes 2C19 and 2D6 in the Turkish population [J].
Aynacioglu, AS ;
Sachse, C ;
Bozkurt, A ;
Kortunay, S ;
Nacak, M ;
Schröder, T ;
Kayaalp, SO ;
Roots, I ;
Brockmöller, J .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1999, 66 (02) :185-192
[5]   Ten percent of North Spanish individuals carry duplicated or triplicated CYP2D6 genes associated with ultrarapid metabolism of debrisoquine [J].
Bernal, ML ;
Sinues, B ;
Johansson, I ;
McLellan, RA ;
Wennerholm, A ;
Dahl, ML ;
Ingelman-Sundberg, M ;
Bertilsson, L .
PHARMACOGENETICS, 1999, 9 (05) :657-660
[6]   Molecular genetics of CYP2D6:: Clinical relevance with focus on psychotropic drugs [J].
Bertilsson, L ;
Dahl, ML ;
Dalén, P ;
Al-Shurbaji, A .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 53 (02) :111-122
[7]   PRONOUNCED DIFFERENCES BETWEEN NATIVE CHINESE AND SWEDISH POPULATIONS IN THE POLYMORPHIC HYDROXYLATIONS OF DEBRISOQUIN AND S-MEPHENYTOIN [J].
BERTILSSON, L ;
LOU, YQ ;
DU, YL ;
LIU, Y ;
KUANG, TY ;
LIAO, XM ;
WANG, KY ;
REVIRIEGO, J ;
ISELIUS, L ;
SJOQVIST, F .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1992, 51 (04) :388-397
[8]   Severe phenytoin intoxication in a subject homozygous for CYP2C9*3 [J].
Brandolese, R ;
Scordo, MG ;
Spina, E ;
Gusella, M ;
Padrini, R .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 70 (04) :391-394
[9]   A MULTIFAMILY STUDY ON THE RELATIONSHIP BETWEEN CYP2C19 GENOTYPE AND S-MEPHENYTOIN OXIDATION PHENOTYPE [J].
BROSEN, K ;
DEMORAIS, SMF ;
MEYER, UA ;
GOLDSTEIN, JA .
PHARMACOGENETICS, 1995, 5 (05) :312-317
[10]   Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: Comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype [J].
Chang, M ;
Dahl, ML ;
Tybring, G ;
Gotharson, E ;
Bertilsson, L .
PHARMACOGENETICS, 1995, 5 (06) :358-363